AETIONOMY clinical study recruitment reaches 200 patients

AETIONOMY an IMI funded project, has now recruited over 200 people into the Parkinson’s Disease portion of the European clinical study on neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. This milestone means that the project is 50% completed in both the AD and the PD portion. The Alzheimer’s disease portion is being recruited via EPAD* which has now recruited a total of 123 subjects of which 58 were recruited at the joint center BBRC.

more info


Developing a “mechanism-based taxonomy” of Alzheimer´s and Parkinson´s Disease.

Currently, the established disease classification systems such as ICD (international classification of disease) make use of phenotypes measured clinically or using standard laboratory and imaging techniques to establish major types and subtypes of diseases.

In contrast to the established disease classification systems, a “mechanism-based taxonomy” is based upon the knowledge about the biological pathways involved in the aetiology of a disease to guide the classification of disease classes and subclasses.

A specific challenge we face in the course of the AETIONOMY project lies in the fact that for most neurodegenerative diseases the dysfunctional biological pathways underlying the disease are not known. AETIONOMY will therefore have to first define new routes towards the identification of the underlying disease mechanisms before organising these and proposing a rational disease taxonomy for Alzheimer’s and Parkinson’s disease. Moreover, we will validate the mechanism-based taxonomy at least partially in the course of a prospective clinical study.



Final AETIONOMY Symposium on Neurodegenerative Research of Alzheimers's and Parkinson's Diseases

About IMI

AETIONOMY is an IMI funded project (EU and EFPIA effort).